Physician profile
Manash Das
NPI 1942467071
$1,255.29
in general payments reported to CMS, 2019-2025
23 companies · $593 in 2025
The $593 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.74 · 2020: $60.38 · 2021: $40.77 · 2022: $55.16 · 2023: $132 · 2024: $296 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $163.59 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $159.27 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $135.92 | 2023-2024 | Cologuard Collection Kit |
| Bioventus LLC | $123.15 | 2025 | Xcell |
| Pfizer INC. | $88.41 | 2019-2025 | |
| Grifols USA, LLC | $75.13 | 2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $57.54 | 2024-2025 | Zerbaxa, Recarbrio, Dificid |
| Amgen INC. | $56.75 | 2025 | Repatha, Evenity |
| Astrazeneca Pharmaceuticals Lp | $55.76 | 2024-2025 | Fasenra, Airsupra |
| Novartis Pharmaceuticals Corporation | $40.52 | 2019 | |
| Electromed, INC. | $36.58 | 2024-2025 | Smartvest |
| Integra Lifesciences Corporation | $32.25 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Insightec,INC | $29.50 | 2025 | Exablate |
| Dexcom, INC. | $26.66 | 2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $25.42 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $24.66 | 2025 | Ohtuvayre |
| Mylan Specialty L.P. | $21.19 | 2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $20.70 | 2025 | Opsumit |
| Celgene Corporation | $20.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.24 | 2022 | |
| Dynavax Technologies Corporation | $15.05 | 2025 | Heplisav-B |
| Sanofi Pasteur INC. | $14.63 | 2019 | |
| Meditrina | $12.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manash Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.